Policy | May 24, 2021
NATCO Pharma receives USFDA approval for Lenalidomide capsules
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.
Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
At the end of the inspection, the facility received two observations, one on written production process control procedure and the other on investigation procedure
Both products are broad-spectrum, foliar insecticides used across wide range of crops
NATCO estimates the current market size of CTPR containing products in India to be over Rs. 2,000 crore.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)